Home > Dermatology > AAD 2022 > New Developments and Unmet Needs in Dermatology > Monitoring is key during JAK inhibitor therapy

Monitoring is key during JAK inhibitor therapy

Presented By
Prof. Jonathan Silverberg
Presented by
Jonathan Silverberg
Conference
AAD 2022
Doi
https://doi.org/10.55788/948cc8a4
Different lectures at the 2022 AAD Annual Meeting dealt with ways to ensure the safe use of Janus kinase (JAK) inhibitors in dermatologic indications. The right choice for the patient and monitoring the therapy are key to successful therapy with these agents. “Severe side effects with JAK inhibitor therapy are probably less common in atopic dermatitis (AD) patients than in the elderly rheumatoid population, but the risk is not zero. We see herpes infections as a class-wide phenomenon,” said Prof. Jonathan Silverberg (George Washington University School of Medicine, Washington DC, USA) in his talk on JAK inhibitors in AD [1]. However, the rates of herpes zoster infections were relatively low in AD trials with abrocitinib, baricitinib, and upadacitinib. Though it should be noted that patients with disseminated herpes zoster and herpes simplex infections and those with recurrent, localised herpes zoster and a history of eczema herpeticum were excluded from th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on